% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Habl:120173,
      author       = {G. Habl and G. Hatiboglu and L. Edler$^*$ and M. Uhl and S.
                      Krause and M. Roethke$^*$ and H.-P. Schlemmer$^*$ and B.
                      Hadaschik and J. Debus$^*$ and K. Herfarth$^*$},
      title        = {{I}on {P}rostate {I}rradiation ({IPI}) - a pilot study to
                      establish the safety and feasibility of primary
                      hypofractionated irradiation of the prostate with protons
                      and carbon ions in a raster scan technique.},
      journal      = {BMC cancer},
      volume       = {14},
      number       = {1},
      issn         = {1471-2407},
      address      = {London},
      publisher    = {BioMed Central},
      reportid     = {DKFZ-2017-00755},
      pages        = {202},
      year         = {2014},
      abstract     = {Due to physical characteristics, ions like protons or
                      carbon ions can administer the dose to the target volume
                      more efficiently than photons since the dose can be lowered
                      at the surrounding normal tissue. Radiation biological
                      considerations are based on the assumption that the α/β
                      value for prostate cancer cells is 1.5 Gy, so that a
                      biologically more effective dose could be administered due
                      to hypofractionation without increasing risks of late
                      effects of bladder (α/β = 4.0) and rectum (α/β =
                      3.9).The IPI study is a prospective randomized phase II
                      study exploring the safety and feasibility of primary
                      hypofractionated irradiation of the prostate with protons
                      and carbon ions in a raster scan technique. The study is
                      designed to enroll 92 patients with localized prostate
                      cancer. Primary aim is the assessment of the safety and
                      feasibility of the study treatment on the basis of incidence
                      grade III and IV NCI-CTC-AE (v. 4.02) toxicity and/or the
                      dropout of the patient from the planned therapy due to any
                      reason. Secondary endpoints are PSA-progression free
                      survival (PSA-PFS), overall survival (OS) and
                      quality-of-life (QoL).This pilot study aims at the
                      evaluation of the safety and feasibility of hypofractionated
                      irradiation of the prostate with protons and carbon ions in
                      prostate cancer patients in an active beam technique.
                      Additionally, the safety results will be compared with
                      Japanese results recently published for carbon ion
                      irradiation. Due to the missing data of protons in this
                      hypofractionated scheme, an in depth evaluation of the
                      toxicity will be created to gain basic data for a following
                      comparison study with carbon ion irradiation.Clinical Trial
                      Identifier: NCT01641185 (clinicaltrials.gov).},
      keywords     = {Prostate-Specific Antigen (NLM Chemicals)},
      cin          = {C060 / E010 / E050},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331 / I:(DE-He78)E010-20160331 /
                      I:(DE-He78)E050-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:24641841},
      pmc          = {pmc:PMC3995364},
      doi          = {10.1186/1471-2407-14-202},
      url          = {https://inrepo02.dkfz.de/record/120173},
}